Mark Ballantyne

Partner at Cooley

Speaker

Mark Ballantyne focuses his practice on representing IPO ready and publicly traded life sciences and technology companies, as well as underwriters.

Mark has provided strategic advice to numerous companies in connection with IPOs, capital markets transactions and Exchange Act reporting. Mark has recently worked on completed securities offerings by companies including 2U, Aclaris, Appian, BigCommerce, Cardlytics, ChannelAdvisor, Clearside, Dova Pharmaceuticals, GlycoMimetics, KemPharm, Legend Biotech, Luna Innovations, Millennial Media, ObsEva, Orphazyme, Senseonics and Verrica Pharmaceuticals.

Mark has also represented various investment banks in capital markets transactions, including BofA Securities, Barclays, Canaccord, Cantor, Cowen, Citigroup, Credit Suisse, Deutsche Bank, Evercore, Goldman Sachs, H.C. Wainwright, Jefferies, J.P. Morgan, Morgan Stanley, Needham, Oppenheimer, Piper Sandler, Raymond James, Stifel, SVB Leerink, UBS, Wedbush, Wells Fargo and William Blair.